Insights and services for generic drug manufacturers

​Generics companies operating in the broader BioPharmaceutical market are being challenged by powerful dynamics including regulatory reforms, the Affordable Care Act, globalization, and the convergence of the Health Care and Life Sciences industries.

Explore content

With a client roster that includes eight of the 10 largest Generics companies,* Deloitte offers a broad array of executable solutions across the business areas of audit, tax, consulting, and financial advisory. Our dedicated industry practitioners work with Generics manufacturers to address both challenges and opportunities, among them:

  • Slowing industry revenue growth: Deloitte helps companies move beyond operating efficiencies and other incremental margin improvements to identify new revenue sources. Offerings include business model performance assessment, portfolio management, M&A strategies, and emerging market/globalization solutions.
  • Shift from small molecules to biologics: Deloitte understands that development and commercialization of biosimilar products is fundamentally different than the traditional Generics business. We have the solutions and capabilities to help our clients build a successful biosimilars business.
  • Outcomes-focused health care: Deloitte professionals work with leaders across the health care value chain, providing insights and access to key players that help to position our clients for a future environment more tightly focused on patient outcomes.
  • Risk, regulatory and compliance: We help Generics companies deal with the multifaceted, evolving regulatory complexities of the industry in which they operate.

*Kennedy Consulting Research & Advisory; Consulting to the Pharmaceutical Sector, 2012; © 2012 Kennedy Information, LLC. Reproduced under license.